B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and rai

The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory ac

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provid

OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation.

OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both s

New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences fas

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX),

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX),

AWM Investment Company Inc. acquired a new stake in OptimizeRx Corp. (NASDAQ: OPRX) in the undefined

Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform

Dimensional Fund Advisors LP grew its position in shares of OptimizeRx Corp. (NASDAQ: OPRX) by 22.3%

OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Conse

OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.0

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst conse

The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Acco

–  Q2 revenue totals $20.5 million–  Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 mill

WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a

OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology

Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, veri

WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a

OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressur

OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life s

Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the

B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and low

Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price

OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.0

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst conse

OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology

Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the

OptimizeRx CEO warns of increased market volatility and uncertainty around MFN pricing. Lower 2026 f

Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the

B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lo

Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price

OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.51 per share which beat the analyst conse